Centinel Spine received FDA 510(k) clearance to market the FLX™ platform of Integrated Interbody™ and non-integrated 3D-printed, all-titanium interbody fusion devices.
FLX is based on the company’s established STALIF interbody devices, in a novel all-titanium lattice option. FLX devices feature solid and porous radiolucent sections designed to offer less mechanical stiffness and better visibility vs. solid titanium implants, as well as a proprietary FUSE-THRU™ trabecular scaffold for bony in-growth and on-growth.
Centinel Spine received FDA 510(k) clearance to market the FLX™ platform of Integrated Interbody™ and non-integrated 3D-printed, all-titanium interbody fusion devices.
FLX is based on the company's established STALIF interbody devices, in a novel all-titanium lattice option. FLX devices feature solid and porous radiolucent sections designed to...
Centinel Spine received FDA 510(k) clearance to market the FLX™ platform of Integrated Interbody™ and non-integrated 3D-printed, all-titanium interbody fusion devices.
FLX is based on the company’s established STALIF interbody devices, in a novel all-titanium lattice option. FLX devices feature solid and porous radiolucent sections designed to offer less mechanical stiffness and better visibility vs. solid titanium implants, as well as a proprietary FUSE-THRU™ trabecular scaffold for bony in-growth and on-growth.
Copy to clipboard 
